Close Menu

NEW YORK — Swedish cancer diagnostics firm Immunovia said on Thursday that it has raised approximately SEK 398 million ($43.0 million) in gross proceeds through the sale of stock to certain institutional investors.

Through the transaction, Immunovia issued 2,948,228 million shares of its stock at a price of SEK 135 apiece to both international and domestic investors. Kempen & Co and Danske Bank acted as joint global coordinators, as well as joint bookrunners along with Vator Securities.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.